{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/hca-healthcare-hca/",
 "dataUrl": "https://clearank.com/stock/hca-healthcare-hca/data.json",
 "title": "HCA Healthcare (HCA) Stock Forecast & Price Target (2026)",
 "description": "HCA Healthcare, Inc. (HCA) stock: Healthcare, Medical Care Facilities. $92.1B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "HCA Healthcare, Inc. (HCA)",
 "published": "2026-07-15T09:29:19+00:00",
 "modified": "2026-09-15T15:17:14.174+00:00",
 "generated": "2026-09-16T12:02:58.089Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "HCA",
  "name": "HCA Healthcare, Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Care Facilities",
  "country": "United States",
  "website": "https://www.hcahealthcare.com"
 },
 "quote": {
  "price": 425.76,
  "previousClose": 425.49,
  "change": 0.27,
  "changePercent": 0.06,
  "open": 418.27,
  "high": 425.8,
  "low": 410.02,
  "volume": 20933,
  "averageVolume": 1309433,
  "marketCap": 92119221069,
  "fiftyTwoWeekHigh": 556.52002,
  "fiftyTwoWeekLow": 353.98999,
  "marketOpen": false,
  "asOf": "2026-09-15T15:17:14.000Z"
 },
 "statistics": {
  "pe": 14.122148,
  "eps": 29.8,
  "dividendYield": 0.007321365716297079,
  "beta": 1.109,
  "priceToSales": 1.1679143,
  "priceToBook": -28.94517304300405,
  "revenueTtm": 78012997632,
  "grossMargin": 0.4475531389026199,
  "returnOnEquity": -2.4482136412847346
 },
 "technicals": {
  "rsi": 47.82,
  "macd": 4.23,
  "sma50": 405.45,
  "sma200": 449.9,
  "rsiSignal": "Neutral",
  "trend": "Bearish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Neutral"
 },
 "analysis": {
  "rating": "Hold",
  "score": 59,
  "consensus": "Hold",
  "fairValue": 435,
  "analystTarget": 435,
  "analystCount": 25,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-15T15:17:14.000Z",
  "priceAtAnalysis": 425.755,
  "volatility": {
   "daily": 1.74,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 421.5,
  "aggressiveEntry": 425.76,
  "stopLoss": 397.18,
  "stopLossPercent": 5.77,
  "targets": [
   434.14,
   442.57,
   455.22
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 313.06,
    "base": 478.75,
    "upside90th": 732.12
   },
   {
    "year": 2028,
    "downside10th": 295.23,
    "base": 538.33,
    "upside90th": 981.61
   },
   {
    "year": 2029,
    "downside10th": 290.05,
    "base": 605.33,
    "upside90th": 1263.33
   },
   {
    "year": 2030,
    "downside10th": 291.06,
    "base": 680.67,
    "upside90th": 1591.81
   },
   {
    "year": 2031,
    "downside10th": 296.06,
    "base": 765.39,
    "upside90th": 1978.72
   },
   {
    "year": 2032,
    "downside10th": 304.06,
    "base": 860.65,
    "upside90th": 2436.13
   },
   {
    "year": 2033,
    "downside10th": 314.55,
    "base": 967.77,
    "upside90th": 2977.49
   },
   {
    "year": 2034,
    "downside10th": 327.3,
    "base": 1088.22,
    "upside90th": 3618.22
   },
   {
    "year": 2035,
    "downside10th": 342.16,
    "base": 1223.67,
    "upside90th": 4376.14
   },
   {
    "year": 2036,
    "downside10th": 359.12,
    "base": 1375.97,
    "upside90th": 5271.96
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "HCA Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$418.27",
    "Day Range": "$410.02 to $425.80",
    "Prev Close": "$425.49",
    "Volume": "20.9K",
    "52-Week Range": "$353.99 to $556.52",
    "Market Cap": "$92.12B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-56%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "HCA Financial Performance",
   "text": [
    "Analysis: In the last 5 quarters, HCA beat estimates 5 times. The stock rose 4 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "HCA Analysis",
   "text": [
    "HCA Healthcare's trading volume has been significantly below average, down 98.4% compared to its daily average, suggesting a lack of strong conviction from market participants. The stock is currently trading above its 50-day and 20-day moving averages, at $405.45 and $416.10 respectively, but remains below its 200-day moving average of $449.90. The Relative Strength Index (RSI) is at 47.82, indicating neutral momentum, neither overbought nor oversold. The chart structure suggests that the 50-day and 20-day moving averages are acting as immediate support levels, while the 200-day moving average presents a key resistance. The MACD indicator is positive at 4.23, but its proximity to zero suggests limited upward momentum. Overall, the technical picture is mixed, with short-term support holding but facing headwinds from the longer-term bearish trend indicated by the price being below the 200-day SMA.",
    "Insiders have sold $38.5 million in HCA Healthcare stock with no reported purchases, indicating a moderate sell signal and potential lack of management confidence.",
    "HCA Healthcare's stock is trading below its 200-day SMA of $449.90, suggesting a bearish technical trend and potential for further downside.",
    "With a 'Hold' consensus rating from 25 analysts, the market sentiment is divided, with a significant portion maintaining neutral stances despite a median price target slightly above the current price.",
    "HCA Healthcare's P/E ratio of 14.12 and P/S ratio of 1.17 are considerably lower than sector averages, suggesting the stock may be undervalued relative to its peers.",
    "The company recently exceeded EPS estimates for the quarter ending June 2026, demonstrating operational resilience and contributing to a positive short-term price reaction.",
    "The base case outlook for HCA Healthcare suggests a potential for recovery towards its 200-day moving average resistance at $449.90, especially if the company can demonstrate improved profitability and a more positive insider sentiment. The median Wall Street price target of $435.00 implies a modest upside of 2.2% from the current price, aligning with a neutral outlook. However, the significant insider selling and the extremely negative return on equity present considerable headwinds. A catalyst for a bullish shift would be a clear improvement in ROE or a reversal in insider transaction trends. Conversely, a failure to regain the 200-day moving average or further negative fundamental developments could lead to a retest of lower support levels, potentially near the $400 mark."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transaction trends closely; a continued moderate sell signal warrants caution.",
     "Pay attention to the 200-day moving average at $449.90 as a key resistance level for HCA Healthcare.",
     "Given the mixed fundamental picture, particularly the negative ROE, consider position sizing carefully."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Signal",
     "text": "Insiders have sold $38.5 million in HCA Healthcare stock with no reported purchases, indicating a moderate sell signal and potential lack of management confidence.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Price Below 200-Day Moving Average",
     "text": "HCA Healthcare's stock is trading below its 200-day SMA of $449.90, suggesting a bearish technical trend and potential for further downside.",
     "source": "Technical Analysis"
    },
    {
     "type": "Neutral",
     "title": "Mixed Wall Street Consensus",
     "text": "With a 'Hold' consensus rating from 25 analysts, the market sentiment is divided, with a significant portion maintaining neutral stances despite a median price target slightly above the current price.",
     "source": "Wall Street Analysts"
    },
    {
     "type": "Bullish",
     "title": "Attractive Valuation Metrics",
     "text": "HCA Healthcare's P/E ratio of 14.12 and P/S ratio of 1.17 are considerably lower than sector averages, suggesting the stock may be undervalued relative to its peers.",
     "source": "Fundamental Analysis"
    },
    {
     "type": "Bullish",
     "title": "Recent Earnings Beat",
     "text": "The company recently exceeded EPS estimates for the quarter ending June 2026, demonstrating operational resilience and contributing to a positive short-term price reaction.",
     "source": "Earnings Report"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "HCA Healthcare's valuation appears attractive on a P/E basis, with its ratio of 14.12 significantly lower than the sector median of 31.9. This is further supported by a price-to-sales ratio of 1.17, which is also below the sector average of 3.7. However, the company's extremely negative return on equity of -244.82% raises concerns about its profitability and efficiency in generating returns for shareholders. The company's operating margin of 15.16% is strong and above the sector median, indicating efficient operations. With a negative debt-to-equity ratio of -0.16, HCA Healthcare possesses a strong balance sheet, suggesting ample financial flexibility. Revenue growth of 8.7% is in line with the sector average, indicating steady top-line expansion.",
    "HCA Healthcare most recently reported earnings for the quarter ending June 2026, with an actual EPS of $7.59, slightly beating the estimated $7.50 by 1.2%. This resulted in a 1.94% increase in the stock price. Prior to this, the company missed estimates in the quarter ending March 2026, reporting an EPS of $0.21 against an estimate of $0.18, with a positive price reaction of 0.61%. The company has shown a pattern of beating estimates in recent quarters, contributing to its overall financial performance.",
    "A primary risk for HCA Healthcare is the moderate insider selling signal, with $38.5 million in sales and no reported purchases, suggesting a lack of confidence from management in the near term. The stock is also trading below its 200-day moving average, indicating a bearish technical trend that could persist. Also, the company's extremely negative return on equity of -244.82% presents a significant fundamental risk, questioning its long-term profitability and capital efficiency."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "92.12B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "14.12"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "29.80"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.70%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "556.52"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "353.99"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Neutral RSI Neutral SMA Cross Bearish Price vs SMA Bullish MACD Bullish Moving averages show a lagging Death Cross (50-day: $405.45, 200-day: $449.90), price sits above the 50-day SMA but below the 200-day SMA - a mixed posture."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bearish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "47.82"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "4.23"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "405.45"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "449.90"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.15",
    "Correlation with Nasdaq 100 (QQQ)": "+0.04",
    "Correlation with Bitcoin (BTC)": "+0.17",
    "Correlation with Gold (XAU)": "+0.02"
   }
  },
  {
   "id": "trade-plans",
   "title": "HCA Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (47.8) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$434.14",
    "TARGET 2": "$442.57",
    "TARGET 3": "$455.22",
    "STOP LOSS": "$397.18"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+5.34%",
    "Average Feb return": "-0.85%",
    "Average Mar return": "-1.94%",
    "Average Apr return": "+0.99%",
    "Average May return": "+1.05%",
    "Average Jun return": "-0.63%",
    "Average Jul return": "+7.95%",
    "Average Aug return": "+2.42%",
    "Average Sep return": "-1.77%",
    "Average Oct return": "+0.75%",
    "Average Nov return": "+4.09%",
    "Average Dec return": "+1.47%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.74%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in HCA in September 2016 would be worth about $56,439 today, compared with about $35,344 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in HCA today could grow to about $32,318 by 2036 in the base case, with a bull case near $123,826 and a bear case around $8,435. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "HCA Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $681 for HCA by 2030 in the base case, from $426 today (1.6x over 4 years). The downside path ends near $291. These are outcomes of a Monte Carlo simulation run on HCA's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using HCA's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "HCA simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$313",
        "$479",
        "$732"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$295",
        "$538",
        "$982"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$290",
        "$605",
        "$1,263"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$291",
        "$681",
        "$1,592"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$296",
        "$765",
        "$1,979"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$304",
        "$861",
        "$2,436"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$315",
        "$968",
        "$2,977"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$327",
        "$1,088",
        "$3,618"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$342",
        "$1,224",
        "$4,376"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$359",
        "$1,376",
        "$5,272"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "RMD ResMed Inc. NYSE $229.44 +2.89%",
     "url": "https://clearank.com/stock/rmd-stock-analysis/"
    },
    {
     "text": "HIMS Hims & Hers Health, Inc. NYSE $27.85 -3.33%",
     "url": "https://clearank.com/stock/hims-hers-health-hims/"
    },
    {
     "text": "OSCR Oscar Health, Inc. NYSE $32.44 -4.05%",
     "url": "https://clearank.com/stock/oscr-stock-analysis/"
    },
    {
     "text": "QDEL QuidelOrtho Corporation NASDAQ $11.12 -5.60%",
     "url": "https://clearank.com/stock/quidelortho-qdel/"
    },
    {
     "text": "BDX Becton, Dickinson and Company NYSE $185.92 +1.65%",
     "url": "https://clearank.com/stock/bdx-stock-analysis/"
    },
    {
     "text": "CRNX Crinetics Pharmaceuticals, Inc. NASDAQ $84.95 +0.00%",
     "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
    },
    {
     "text": "OFIX Orthofix Medical Inc. NASDAQ $9.09 -0.22%",
     "url": "https://clearank.com/stock/ofix-stock-analysis/"
    },
    {
     "text": "CRSP CRISPR Therapeutics AG NASDAQ $51.83 -2.13%",
     "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "T vs VZ Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/t-vs-vz/"
    },
    {
     "text": "LINK/USD vs XRP/USD Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/link-vs-xrp/"
    },
    {
     "text": "VTI vs SCHB Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vti-vs-schb/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "HCA Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$38.5M",
    "Insiders": "17",
    "Avg Transaction": "$4.8M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in HCA",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Apr 30, 2021",
       "cells": [
        "WATERMAN ROBERT A General Counsel",
        "Sell",
        "147.5K",
        "$29.6M"
       ]
      },
      {
       "label": "Feb 3, 2026",
       "cells": [
        "HAZEN SAMUEL N Chief Executive Officer",
        "Sell",
        "42.9K",
        "$21.5M"
       ]
      },
      {
       "label": "Apr 27, 2021",
       "cells": [
        "PERLIN JONATHAN B Officer",
        "Sell",
        "100.7K",
        "$20.1M"
       ]
      },
      {
       "label": "May 5, 2021",
       "cells": [
        "WATERMAN ROBERT A General Counsel",
        "Sell",
        "81.3K",
        "$16.8M"
       ]
      },
      {
       "label": "Nov 3, 2020",
       "cells": [
        "HAZEN SAMUEL N Chief Executive Officer",
        "Sell",
        "121.9K",
        "$16.5M"
       ]
      },
      {
       "label": "Feb 24, 2021",
       "cells": [
        "WATERMAN ROBERT A General Counsel",
        "Sell",
        "73.9K",
        "$13.1M"
       ]
      },
      {
       "label": "Nov 2, 2021",
       "cells": [
        "HAZEN SAMUEL N Chief Executive Officer",
        "Sell",
        "50.0K",
        "$12.6M"
       ]
      },
      {
       "label": "Feb 5, 2021",
       "cells": [
        "WATERMAN ROBERT A General Counsel",
        "Sell",
        "62.9K",
        "$11.2M"
       ]
      },
      {
       "label": "Aug 2, 2021",
       "cells": [
        "PERLIN JONATHAN B Officer",
        "Sell",
        "40.0K",
        "$10.0M"
       ]
      },
      {
       "label": "Feb 3, 2023",
       "cells": [
        "RUTHERFORD BILL B Chief Financial Officer",
        "Sell",
        "30.0K",
        "$7.7M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=HCA+Healthcare%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is HCA Healthcare stock a buy right now?",
   "answer": "HCA Healthcare is currently rated as a Hold by Wall Street analysts, with a consensus score of 59 out of 100. While the stock trades below its 200-day moving average and shows moderate insider selling, its valuation metrics and recent earnings performance offer some support."
  },
  {
   "question": "What is HCA Healthcare's price target for 2030?",
   "answer": "Based on Monte Carlo simulations, HCA Healthcare's base case price projection for 2030 is $680.67, with a downside projection of $291.06. These are statistical outcomes, not guarantees, and represent a significant range of potential future values."
  },
  {
   "question": "What are the key technical levels for HCA Healthcare stock?",
   "answer": "HCA Healthcare is currently trading above its 50-day ($405.45) and 20-day ($416.10) moving averages, which are acting as support. However, the stock remains below its 200-day moving average ($449.90), which serves as a key resistance level, indicating a bearish longer-term technical trend."
  },
  {
   "question": "What is the Wall Street consensus on HCA Healthcare stock?",
   "answer": "The Wall Street consensus for HCA Healthcare is 'Hold', with 25 analysts covering the stock. This includes 1 Strong Buy, 13 Buy, 10 Hold, and 1 Sell rating, resulting in a Wall Street score of 59 out of 100."
  },
  {
   "question": "How has HCA Healthcare performed in recent earnings reports?",
   "answer": "HCA Healthcare recently beat earnings estimates for the quarter ending June 2026, reporting $7.59 per share against an estimate of $7.50, leading to a 1.94% stock price increase. The company has generally shown a pattern of meeting or exceeding earnings expectations."
  },
  {
   "question": "What is the insider sentiment for HCA Healthcare?",
   "answer": "Insider sentiment for HCA Healthcare is currently negative, with a 'Moderate Sell Signal' indicated. Insiders have sold a total of $38.5 million worth of stock, with no reported purchases, suggesting a cautious outlook from management."
  },
  {
   "question": "How does HCA Healthcare's valuation compare to its sector peers?",
   "answer": "HCA Healthcare's P/E ratio of 14.12 and price-to-sales ratio of 1.17 are significantly lower than the sector medians of 31.9 and 3.7, respectively. This suggests HCA is trading at a discount to its peers, although its return on equity is substantially weaker."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "RMD",
    "name": "ResMed Inc. NYSE",
    "price": "$229.44",
    "change": "+2.89%",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "HIMS",
    "name": "Hims & Hers Health, Inc. NYSE",
    "price": "$27.85",
    "change": "-3.33%",
    "url": "https://clearank.com/stock/hims-hers-health-hims/"
   },
   {
    "ticker": "OSCR",
    "name": "Oscar Health, Inc. NYSE",
    "price": "$32.44",
    "change": "-4.05%",
    "url": "https://clearank.com/stock/oscr-stock-analysis/"
   },
   {
    "ticker": "QDEL",
    "name": "QuidelOrtho Corporation NASDAQ",
    "price": "$11.12",
    "change": "-5.60%",
    "url": "https://clearank.com/stock/quidelortho-qdel/"
   },
   {
    "ticker": "BDX",
    "name": "Becton, Dickinson and Company NYSE",
    "price": "$185.92",
    "change": "+1.65%",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   },
   {
    "ticker": "CRNX",
    "name": "Crinetics Pharmaceuticals, Inc. NASDAQ",
    "price": "$84.95",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "OFIX",
    "name": "Orthofix Medical Inc. NASDAQ",
    "price": "$9.09",
    "change": "-0.22%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "CRSP",
    "name": "CRISPR Therapeutics AG NASDAQ",
    "price": "$51.83",
    "change": "-2.13%",
    "url": "https://clearank.com/stock/crispr-therapeutics-crsp/"
   }
  ],
  "comparisons": [
   {
    "ticker": "T vs VZ Comparison",
    "name": "",
    "url": "https://clearank.com/compare/t-vs-vz/"
   },
   {
    "ticker": "LINK/USD vs XRP/USD Comparison",
    "name": "",
    "url": "https://clearank.com/compare/link-vs-xrp/"
   },
   {
    "ticker": "VTI vs SCHB Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vti-vs-schb/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "NTES",
    "text": "NetEase, Inc.",
    "url": "https://clearank.com/stock/ntes-stock-analysis/"
   },
   {
    "ticker": "PCAR",
    "text": "PACCAR Inc.",
    "url": "https://clearank.com/stock/pcar-stock-analysis/"
   },
   {
    "ticker": "O",
    "text": "Realty Income Corp.",
    "url": "https://clearank.com/stock/o-stock-analysis/"
   },
   {
    "ticker": "SPG",
    "text": "Simon Property Group Inc.",
    "url": "https://clearank.com/stock/spg-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "ARB/USD",
    "text": "↑ 19.42%",
    "url": "https://clearank.com/crypto/arbitrum-arb-usd/"
   },
   {
    "ticker": "INJ/USD",
    "text": "↓ 11.80%",
    "url": "https://clearank.com/crypto/injective-inj/"
   },
   {
    "ticker": "CRV/USD",
    "text": "↓ 11.53%",
    "url": "https://clearank.com/crypto/crv-usd-crypto-analysis/"
   },
   {
    "ticker": "CRCL",
    "text": "↓ 11.41%",
    "url": "https://clearank.com/stock/circle-internet-group-crcl/"
   },
   {
    "ticker": "TEM",
    "text": "↑ 10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "AGL",
    "text": "Agilon Health Inc",
    "url": "https://clearank.com/stock/agl-stock-analysis/"
   },
   {
    "ticker": "GEHC",
    "text": "GE HealthCare",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "HIMS",
    "text": "Hims & Hers",
    "url": "https://clearank.com/stock/hims-hers-health-hims/"
   },
   {
    "ticker": "HUM",
    "text": "Humana Inc",
    "url": "https://clearank.com/stock/hum-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/HCA-hca-healthcare-hca-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/HCA-hca-healthcare-hca-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "HCA Healthcare (HCA) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/hca-healthcare-hca/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/hca-healthcare-hca/",
        "name": "HCA Healthcare (HCA) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/hca-healthcare-hca/#webpage",
     "url": "https://clearank.com/stock/hca-healthcare-hca/",
     "name": "HCA Healthcare (HCA) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-15T09:29:19+00:00",
     "dateModified": "2026-09-15T15:17:14+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/HCA-hca-healthcare-hca-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/hca-healthcare-hca/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/hca-healthcare-hca/#richSnippet",
     "headline": "HCA Healthcare (HCA) Stock Forecast & Price Target (2026)",
     "name": "HCA Healthcare (HCA) Stock Forecast & Price Target (2026)",
     "description": "HCA Healthcare, Inc. (HCA) stock: Healthcare, Medical Care Facilities. $92.1B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-15T09:29:19+00:00",
     "dateModified": "2026-09-15T15:17:14+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "HCA Healthcare, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "HCA"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "HCA Healthcare, Inc. is a healthcare services company that operates a broad network of hospitals, ambulatory surgery centers, freestanding emergency rooms, urgent care clinics, physician practices, diagnostic and imaging centers, rehabilitation facilities, and other care sites. The company serves pa",
      "tickerSymbol": "HCA",
      "sameAs": "https://www.hcahealthcare.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/hca-healthcare-hca/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/HCA-hca-healthcare-hca-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/hca-healthcare-hca/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is HCA Healthcare stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "HCA Healthcare is currently rated as a Hold by Wall Street analysts, with a consensus score of 59 out of 100. While the stock trades below its 200-day moving average and shows moderate insider selling, its valuation metrics and recent earnings performance offer some support."
     }
    },
    {
     "@type": "Question",
     "name": "What is HCA Healthcare's price target for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, HCA Healthcare's base case price projection for 2030 is $680.67, with a downside projection of $291.06. These are statistical outcomes, not guarantees, and represent a significant range of potential future values."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical levels for HCA Healthcare stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "HCA Healthcare is currently trading above its 50-day ($405.45) and 20-day ($416.10) moving averages, which are acting as support. However, the stock remains below its 200-day moving average ($449.90), which serves as a key resistance level, indicating a bearish longer-term technical trend."
     }
    },
    {
     "@type": "Question",
     "name": "What is the Wall Street consensus on HCA Healthcare stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The Wall Street consensus for HCA Healthcare is 'Hold', with 25 analysts covering the stock. This includes 1 Strong Buy, 13 Buy, 10 Hold, and 1 Sell rating, resulting in a Wall Street score of 59 out of 100."
     }
    },
    {
     "@type": "Question",
     "name": "How has HCA Healthcare performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "HCA Healthcare recently beat earnings estimates for the quarter ending June 2026, reporting $7.59 per share against an estimate of $7.50, leading to a 1.94% stock price increase. The company has generally shown a pattern of meeting or exceeding earnings expectations."
     }
    },
    {
     "@type": "Question",
     "name": "What is the insider sentiment for HCA Healthcare?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider sentiment for HCA Healthcare is currently negative, with a 'Moderate Sell Signal' indicated. Insiders have sold a total of $38.5 million worth of stock, with no reported purchases, suggesting a cautious outlook from management."
     }
    },
    {
     "@type": "Question",
     "name": "How does HCA Healthcare's valuation compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "HCA Healthcare's P/E ratio of 14.12 and price-to-sales ratio of 1.17 are significantly lower than the sector medians of 31.9 and 3.7, respectively. This suggests HCA is trading at a discount to its peers, although its return on equity is substantially weaker."
     }
    }
   ]
  }
 ]
}